Toxicological considerations in the treatment of axial spondylo-arthritis

References

• Braun J, Dougados M, Baeten D. Axial spondyloarthritis. Nat Rev Dis Primers. 2015;1:15013.
   Google Scholar
• Burgos-Vargas R. Undifferentiated spondyloarthritis: a global perspective. Curr Rheumatol Rep. 2007;9(5):361–366.
   Google Scholar
• Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127–2137.
   Google Scholar
• Olivieri I, D’Angelo S, Padula A, et al. Spondyloarthritis with onset after age 45. Curr Rheumatol Rep. 2013;15(12):374
   Google Scholar
• Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34(10):1218–1227.
   Google Scholar
• Amor B, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic. 1990;57(2):85–89.
   Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783.
   Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31.
   Google Scholar
• Sieper J. Review: nonradiographic axial spondyloarthritis: new definition of an old disease? Arthritis Rheum. 2013;65(3):543–551.
   Google Scholar
• Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis. 2005;64(10):1431–1435.
   Google Scholar
• Guillemin F, Saraux A, Guggenbuhl P, et al. Prevalence of rheumatoid arthritis in France: 2001. Ann Rheum Dis. 2005;64(10):1427–1430.
   Google Scholar
• Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1–44.
   Google Scholar
• Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis. 2009;68(6):784–788.
   Google Scholar
• Van Der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991.
   Google Scholar
• Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599–1613.
   Google Scholar
• Sieper J, Lenaerts J, Wollenhaupt J, et al. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis. 2014;73(1):101–107.
   Google Scholar
• Van der Heijde D, Baraf HS, Ramos-Remus C, et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 2005;52(4):1205–1215.
   Google Scholar
• Amor B, Dougados M, Listrat V. et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria?. Rev Rhum Engl Ed.. 1995;62(1):10–15.
   Google Scholar
• Wanders A, Heijde D, Landewé R, et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–1765.
   Google Scholar
• Sieper J, Listing J, Poddubnyy D, et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis. 2016;75(8):1438–1443.
   Google Scholar
• Ward MM, Deodhar A, Akl EA, et al. American college of rheumatology/spondylitis association of Ameri-ca/spondyloarthritis research and treatment network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheum. 2016;68(2):282–298.
   Google Scholar
• Poddubnyy D, van der Heijde D. Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin North Am. 2012;38(3):601–611.
   Google Scholar
• Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894):769–779.
   Google Scholar
• Song IH, Poddubnyy DA, Rudwaleit M, et al. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2008;58(4):929–938.
   Google Scholar
• Kristensen LE, Jakobsen AK, Askling J, et al. Safety of etoricoxib, celecoxib, and nonselective nonsteroidal antiinflammatory drugs in ankylosing spondylitis and other spondyloarthritis patients: a Swedish national population-based cohort study. Arthritis Care Res (Hoboken). 2015;67(8):1137–1149.
   Google Scholar
• Dougados M, Gueguen A, Nakache JP, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford). 1999;38(3):235–244.
   Google Scholar
• Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015;7:CD010952.
   Google Scholar
• Bakland G, Gran JT, Nossent JC. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis. 2011;70(11):1921–1925.
   Google Scholar
• Haroon NN, Paterson JM, Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med. 2015;163(6):409–416.
   Google Scholar
• Haibel H, Fendler C, Listing J, et al. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis. 2014;73(1):243–246.
   Google Scholar
• Van der Horst-bruinsma IE, Clegg DO, Dijkmans BA. Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S67–S70.
   Google Scholar
• Nissilä M, Lehtinen K, Leirisalo-Repo M, et al. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum. 1988;31(9):1111–1116.
   Google Scholar
• Braun J, Zochling J, Baraliakos X, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 2006;65(9):1147–1153.
   Google Scholar
• Breban M, Ravaud P, Claudepierre P, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on demand treatment. Arthritis Rheum. 2008;58(1):88–97.
   Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–485.
   Google Scholar
• Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol. 2005;53(4):652–659.
   Google Scholar
• Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795–810.
   Google Scholar
• Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opin Pharmacother. 2016;17:1539–1547.
   Google Scholar
• Chen J, Lin S, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2014;11:CD004800.
   Google Scholar
• Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187–1193.
   Google Scholar
• Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondyli-tis: results of a randomized, double-blind, placebo-controlled, Phase III trial. Arthritis Rheum. 2008;58(11):3402–3412.
   Google Scholar
• van der Heijde D, Sieper J, WP M, et al. 2010 update of the international ASAS recommenda-tions for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905–908.
   Google Scholar
• Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY 1). Ann Rheum Dis. 2013;72:815–822.
   Google Scholar
• Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24 week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73(1):39–47.
   Google Scholar
• Gao X, Wendling D, Botteman MF, et al. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents. J Med Econ. 2012;15(6):1054–1063.
   Google Scholar
• Cobo-Ibanez T, Ordonez MDC, Munoz-Fernandez S, et al. Do TNF-blockers reduce or induce uveitis? Rheumatology. 2008;47(5):731–732.
   Google Scholar
• Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum. 2003;48(4):1126–1136.
   Google Scholar
• Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis. Ann Rheum Dis. 2004;63(6):665–670.
   Google Scholar
• Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011;70(6):973–981.
   Google Scholar
• Carmona L, Descalzo MA, Ruiz-Montesinos D, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford). 2011;50(1):85–92.
   Google Scholar
• Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine. 2002;69(1):12–18.
   Google Scholar
• Atzeni F, Gianturco L, Talotta R, et al. Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern? Immunotherapy. 2015;7(4):353–361.
   Google Scholar
• HUMIRA: Highlights of prescribing information. [cited 2016 Nov 21]. Available from: http://www.rxabbvie.com/pdf/humira.pdf
   Google Scholar
• ENBREL: Highlights of prescribing information. [cited 2016 Nov 21]. Available from: http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf
   Google Scholar
• Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;18(4):CD005468.
   Google Scholar
• Qiang T, Qing C, Tristan DM, et al. Adverse events of anti-tumor necrosis factor α therapy in ankylosing spondylitis. PLoS ONE. 2015;10(4):e0127488.
   Google Scholar
• Keane J, Bresnihan B. Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies. Curr Opin Rheumatol. 2008;20(4):443–449.
   Google Scholar
• Dittmar M. Human biological research since 2006 at the Christian-AlbrechtsUniversity in Kiel--aging, chrono-biology, and high altitude adaptation. Anthropol Anz. 2014;71(1–2):143–153.
   Google Scholar
• Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2(11):602–610.
   Google Scholar
• Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl. 2014;91:47–55.
   Google Scholar
• Palazzi C, D’Angelo S, Leccese P, et al. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update. Expert Opin Drug Saf. 2014;13(2):191–196.
   Google Scholar
• Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infec-tion requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015;14(6):503–509.
   Google Scholar
• Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–2376.
   Google Scholar
• Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005;52(11):3403–3412.
   Google Scholar
• Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious in-fections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50(1):124–131.
   Google Scholar
• Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis. 2011;70(11):1914–1920.
   Google Scholar
• Atzeni F, Sarzi Puttini P, Botsios C, et al. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev. 2012;12(2):225–229.
   Google Scholar
• Filippini M, Bazzani C, Favalli EG, et al. Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. Clin Rev Allergy Immunol. 2010;38(2–3):90–96.
   Google Scholar
• Singh JA, Cameron C, Noorbaloochi S, et al. The risk of serious infection with biologics in treating patients with rheumatoid arthritis: A Systematic Review and Meta-analysis. Lancet. 2015: 250–265.
   Google Scholar
• Selmi C, Ceribelli A, Naguwa SM, et al. Safety issues and concerns of new immunomodulators in rheumatology. Expert Opin Drug Saf. 2015;14(3):389–399.
   Google Scholar
• D’Angelo S, Carriero A, Gilio M, et al. Safety of treatment options for spondyloarthritis: a narrative review. Expert Opin Drug Saf. 2018;17(5):475–486.
   Google Scholar
• Che H, Lukas C, Morel J, et al. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014;81(3):215–221.
   Google Scholar
• Harpaz R, Ortega Sanchez I, Seward J. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2008;57(5):1–16.
   Google Scholar
• Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.
   Google Scholar
• Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64(6):1035–1050.
   Google Scholar
• Bombardier C, Hazlewood GS, Akhavan P, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J Rheumatol. 2012;39(8):1583–1602.
   Google Scholar
• Singh JA, Furst DE, Bharat A, et al. Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;2012(64):625–639.
   Google Scholar
• Mercer LK, Lunt M, Low ALS, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015;74:1087–1093.
   Google Scholar
• Marino F, Nucera V, Gerratana E, et al. Cancer risk and tumour necrosis factor inhibi-tors in patients with inflammatory arthritis. Pharmacol Res. 2019;158:104507.
   Google Scholar
• Hellgren K, Dreyer L, Arkema EV, et al. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers. Ann Rheum Dis. 2017;76:105–111.
   Google Scholar
• Chen Y, Sun J, Yang Y, et al. Malignancy risk of anti-tumor necrosis factor alpha blockers: an over-view of systematic reviews and meta-analyses. Clin Rheumatol. 2016;35:1–18.
   Google Scholar
• Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moder- ate-to severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133–3140.
   Google Scholar
• Atzeni F, Benucci M, Sallì S, et al. Different effects of biological drugs in rheumatoid arthritis. Autoimmun Rev. 2013;12(5):575–579.
   Google Scholar
• Atzeni F, Talotta R, Masala IF, et al. Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. Best Pract Res Clin Rheumatol. 2018;32(4):500–510.
   Google Scholar
• Kay J, Fleischmann R, Keystone E, et al. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebocontrolled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Ann Rheum Dis. 2015;74(3):538–546.
   Google Scholar
• Hamzaoglu H, Cooper J, Alsahli M, et al. Safety of infliximab in Crohn’s disease: a large single-center experience. Inflamm Bowel Dis. 2010;16(12):2109–2116.
   Google Scholar
• Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis. 2007;66(6):732–739.
   Google Scholar
• Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(3):373–382.
   Google Scholar
• Faillace C, de Almeida JR, de Carvalho JF. Optic neuritis after infliximab therapy. Rheumatol Int. 2013;33(4):1101–1103.
   Google Scholar
• Fromont A, De Seze J, Fleury MC, et al. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine. 2009;45(2):55–57.
   Google Scholar
• Paine A, Ritchlin CT. Targeting the interleukin-23/17 axis in axial spondyloarthritis. Curr Opin Rheumatol. 2016;28:359–367.
   Google Scholar
• Mei Y, Pan F, Gao J. et al. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheum. 2011;30(2):269–273.
   Google Scholar
• Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis sug-gests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive im-mune response. Arthritis Res Ther. 2011;13(3):R95.
   Google Scholar
• van den Berg WB, McInnes IB. Th17 cells and IL-17 a–focus on immunopathogenesis and immunotherapeu-tics. Semin Arthritis Rheum. 2013;43(2):158–170.
   Google Scholar
• Babaie F, Hasankhau M, Mohammadi H, et al. The role of gut microbiota and IL-23/IL-17 pathway in ankylosing spondylitis immunopathogenesis: new insights and updates. Immunol Lett. 2018;196:52–62.
   Google Scholar
• Baeten DL, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin 17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52 week Phase 3 randomized pla-cebo controlled trial with intravenous loading and subcutaneous maintenance dosing. Arthritis Rheum. 2014;66(Suppl):S360.
   Google Scholar
• Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo controlled trial. Lancet. 2013;382:1705–1713.
   Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–2538.
   Google Scholar
• Lubrano E, Perrotta FM. Secukinumab for ankylosing spondylitis and psoriatic arthritis. Ther Clin Risk Manag. 2016;12:1587–1592.
   Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19:285.
   Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–1146.
   Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–1339.
   Google Scholar
• Baraliakos X, Kivitz AJ, Deodhar AA, et al. Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial. Clin Exp Rheumatol. 2018;36(1):50–55.
   Google Scholar
• Braun J, Baraliakos X, Deodhar A, et al. Effect of secukinumab on clinical and radiographic outcomes in anky-losing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis. 2017;76:1070–1077.
   Google Scholar
• Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology. 2014;53:213–222.
   Google Scholar
• Poddubnyy D, Amital H, Rubbert-Roth A. Should we combine biologics with methotrexate in axial spondyloarthritis? Autoimmun Rev. 2019;18(12):102402.
   Google Scholar
• Wendling D, Prati C. Paradoxical effects of anti-TNF-α agents in inflammatory diseases. Exp Rev Clinical Imm. 2013;10:159–169.
   Google Scholar